Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Sydes

Showing results (11-20 of 213) with videos related to

Pageof 22
Sort By:
European Urology Focus|February 27, 2019
Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"?Jeffrey Shevach, Matthew R Sydes, Maha Hussain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Early salvage radiotherapy after radical prostatectomyChristopher Parker, Charles Catton, Matthew R Sydes
BJU International|December 24, 2015
Will chemotherapy change the management of prostate cancer?Clare Gilson, Matthew R Sydes, Simon Chowdhury
European Urology|March 24, 2009
Re: Ofer Yossepowitch, Anders Bjartell, James A. Eastham, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55:87-99Howard Kynaston, Christopher C Parker, Matthew R Sydes, et al.
BMJ Open|October 20, 2018
Cross-sectional analysis of UK research studies in 2015: results from a scoping project with the UK Health Research AuthorityTim Clark, Richard H Wicentowski, Matthew R Sydes
Fertility and Sterility|March 17, 2024
When to randomize patients in a randomized controlled trial?Sarah Lensen, Matthew R Sydes, Alex Polyakov, et al.
Lancet (London, England)|July 29, 2014
More multiarm randomised trials of superiority are neededMahesh K B Parmar, James Carpenter, Matthew R Sydes
International Journal of Radiation Oncology, Biology, Physics|November 26, 2011
Adjuvant radiotherapy after prostatectomy: does waiting for a detectable prostate-specific antigen level make sense?: in regard to King CR (Int J Radiat Oncol Biol Phys 2011;80:1-3)Charles N Catton, Christopher C Parker, Matthew R Sydes
The New England Journal of Medicine|October 26, 2017
Abiraterone in Metastatic Prostate CancerNicholas D James, Melissa R Spears, Matthew R Sydes
BMC Medicine|November 26, 2016
How do you design randomised trials for smaller populations? A frameworkMahesh K B Parmar, Matthew R Sydes, Tim P Morris
Pageof 22

Showing results (11-20 of 213) with videos related to

Sort By:
Pageof 22
European Urology Focus|February 27, 2019
Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order"?Jeffrey Shevach, Matthew R Sydes, Maha Hussain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Early salvage radiotherapy after radical prostatectomyChristopher Parker, Charles Catton, Matthew R Sydes
BJU International|December 24, 2015
Will chemotherapy change the management of prostate cancer?Clare Gilson, Matthew R Sydes, Simon Chowdhury
European Urology|March 24, 2009
Re: Ofer Yossepowitch, Anders Bjartell, James A. Eastham, et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009;55:87-99Howard Kynaston, Christopher C Parker, Matthew R Sydes, et al.
BMJ Open|October 20, 2018
Cross-sectional analysis of UK research studies in 2015: results from a scoping project with the UK Health Research AuthorityTim Clark, Richard H Wicentowski, Matthew R Sydes
Fertility and Sterility|March 17, 2024
When to randomize patients in a randomized controlled trial?Sarah Lensen, Matthew R Sydes, Alex Polyakov, et al.
Lancet (London, England)|July 29, 2014
More multiarm randomised trials of superiority are neededMahesh K B Parmar, James Carpenter, Matthew R Sydes
International Journal of Radiation Oncology, Biology, Physics|November 26, 2011
Adjuvant radiotherapy after prostatectomy: does waiting for a detectable prostate-specific antigen level make sense?: in regard to King CR (Int J Radiat Oncol Biol Phys 2011;80:1-3)Charles N Catton, Christopher C Parker, Matthew R Sydes
The New England Journal of Medicine|October 26, 2017
Abiraterone in Metastatic Prostate CancerNicholas D James, Melissa R Spears, Matthew R Sydes
BMC Medicine|November 26, 2016
How do you design randomised trials for smaller populations? A frameworkMahesh K B Parmar, Matthew R Sydes, Tim P Morris
Pageof 22